Atara Biotherapeutics, Inc. SEC filings ATRA
Atara Biotherapeutics, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Jul 9, 2015. Its latest annual report, Form 10-K, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jun 12, 2026 | — |
| 424B5 | Prospectus supplement | May 12, 2026 | — |
| 424B3 | Prospectus | Mar 25, 2026 | — |
| S-3 | Shelf registration | Mar 17, 2026 | — |
| 424B5 | Prospectus supplement | Mar 16, 2026 | — |
| 424B5 | Prospectus supplement | May 15, 2025 | — |
| S-8 | Employee stock plan registration | Jan 17, 2025 | — |
| 424B5 | Prospectus supplement | Sep 4, 2024 | — |
| S-8 | Employee stock plan registration | Jun 11, 2024 | — |
| S-8 | Employee stock plan registration | Jun 11, 2024 | — |
| 424B5 | Prospectus supplement | Jan 9, 2024 | — |
| S-8 | Employee stock plan registration | Jan 3, 2024 | — |
| 424B3 | Prospectus | Nov 17, 2023 | — |
| S-3 | Shelf registration | Nov 1, 2023 | — |
| POS AM | Filing | Feb 9, 2023 | — |
| S-8 | Employee stock plan registration | Feb 9, 2023 | — |
| S-8 | Employee stock plan registration | Jul 22, 2022 | — |
| S-8 | Employee stock plan registration | Feb 28, 2022 | — |
| 424B5 | Prospectus supplement | Nov 26, 2021 | — |
| S-8 | Employee stock plan registration | Sep 29, 2021 | — |
| S-8 | Employee stock plan registration | Mar 1, 2021 | — |
| S-3ASR | Automatic shelf registration | Mar 1, 2021 | — |
| 424B5 | Prospectus supplement | Dec 9, 2020 | — |
| 424B5 | Prospectus supplement | Dec 7, 2020 | — |
| S-8 | Employee stock plan registration | Nov 9, 2020 | — |
| 424B5 | Prospectus supplement | May 27, 2020 | — |
| 424B5 | Prospectus supplement | May 26, 2020 | — |
| S-8 | Employee stock plan registration | Feb 27, 2020 | — |
| 424B5 | Prospectus supplement | Feb 27, 2020 | — |
| 424B5 | Prospectus supplement | Jul 19, 2019 | — |
| 424B5 | Prospectus supplement | Jul 18, 2019 | — |
| S-8 | Employee stock plan registration | Feb 26, 2019 | — |
| 424B5 | Prospectus supplement | Feb 26, 2019 | — |
| 424B5 | Prospectus supplement | Mar 1, 2018 | — |
| 424B5 | Prospectus supplement | Feb 27, 2018 | — |
| S-3ASR | Automatic shelf registration | Feb 27, 2018 | — |
| S-8 | Employee stock plan registration | Feb 27, 2018 | — |
| 424B5 | Prospectus supplement | Jan 4, 2018 | — |
| FWP | Free writing prospectus | Jan 3, 2018 | — |
| 424B5 | Prospectus supplement | Jan 2, 2018 | — |
| S-8 | Employee stock plan registration | Aug 7, 2017 | — |
| 424B5 | Prospectus supplement | Mar 27, 2017 | — |
| S-8 | Employee stock plan registration | Nov 4, 2016 | — |
| S-8 | Employee stock plan registration | Mar 4, 2016 | — |
| S-3 | Shelf registration | Nov 9, 2015 | — |
| 424B1 | Filing | Jul 10, 2015 | — |
| S-1MEF | Filing | Jul 9, 2015 | — |
| S-1/A | Amended registration statement | Jul 9, 2015 | — |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ATRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Thousand Oaks, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1604464
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.